Edition:
United Kingdom

Stemline Therapeutics Inc (STML.OQ)

STML.OQ on NASDAQ Stock Exchange Capital Market

10.05USD
16 Jan 2019
Change (% chg)

-- (--)
Prev Close
$10.05
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
130,215
52-wk High
$20.55
52-wk Low
$7.86

Chart for

About

Stemline Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the... (more)

Overall

Beta: -0.12
Market Cap(Mil.): $302.10
Shares Outstanding(Mil.): 25.28
Dividend: --
Yield (%): --

Financials

  STML.OQ Industry Sector
P/E (TTM): -- 69.71 34.38
EPS (TTM): -2.44 -- --
ROI: -65.15 8.99 14.96
ROE: -65.34 10.13 16.53

U.S. FDA approves Stemline Therapeutics' rare blood disease treatment

The U.S. Food and Drug Administration on Friday approved Stemline Therapeutics Inc's Elzonris for the treatment of a rare blood disease in adults and children aged two years and above.

21 Dec 2018

UPDATE 2-U.S. FDA approves Stemline Therapeutics' rare blood disease treatment

Dec 21 The U.S. Food and Drug Administration on Friday approved Stemline Therapeutics Inc's Elzonris for the treatment of a rare blood disease in adults and children aged two years and above.

21 Dec 2018

U.S. FDA approves Stemline Therapeutics' rare blood disease treatment

Dec 21 The U.S. Food and Drug Administration on Friday approved Stemline Therapeutics Inc's Elzonris for the treatment of a rare blood disease in adults and children aged two years and above.

21 Dec 2018

Earnings vs. Estimates